NUMIF (Numinus Wellness) YoY EBITDA Growth: 90.00% (As of May. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Numinus Wellness YoY EBITDA Growth?

Numinus Wellness NUMIF -9.83% YoY EBITDA Growth is 90.00% as of May. 2025.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Numinus Wellness's YoY EBITDA Growth for the quarter that ended in May. 2025 was 90.00%.

Numinus Wellness's EBITDA per Share for the three months ended in May. 2025 was $-0.00.

Numinus Wellness YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Numinus Wellness's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Numinus Wellness YoY EBITDA Growth Chart

Numinus Wellness Annual Data
Trend Aug19 Aug20 Aug21 Aug22 Aug23 Aug24
YoY EBITDA Growth
Get a 7-Day Free Trial -50.00 18.10 -77.91 59.48 43.55

Numinus Wellness Quarterly Data
Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 54.55 66.67 80.00 -69.23 90.00

Numinus Wellness YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Numinus Wellness's YoY EBITDA Growth for the fiscal year that ended in Aug. 2024 is calculated as:

YoY EBITDA Growth (A: Aug. 2024 )
=(EBITDA per Share (A: Aug. 2024 )-EBITDA per Share (A: Aug. 2023 ))/ | EBITDA per Share (A: Aug. 2023 ) |
=(-0.035--0.062)/ | -0.062 |
=43.55 %

Numinus Wellness's YoY EBITDA Growth for the quarter that ended in May. 2025 is calculated as:

YoY EBITDA Growth (Q: May. 2025 )
=(EBITDA per Share (Q: May. 2025 )-EBITDA per Share (Q: May. 2024 )) / | EBITDA per Share (Q: May. 2024 )) |
=(-0.001--0.01)/ | -0.01 |
=90.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 90.00% mean?
Numinus Wellness (NUMIF) has a YoY EBITDA Growth of 90.00% as of May. 2025. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Numinus Wellness and its competitors.
Is Numinus Wellness' YoY EBITDA Growth too high?
Numinus Wellness' current YoY EBITDA Growth is 90.00%.
How does Numinus Wellness' YoY EBITDA Growth compare to HLYK and SYRA?
Numinus Wellness' YoY EBITDA Growth of 90.00% can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Healthcare Providers & Services company?
A good YoY EBITDA Growth depends on the Healthcare Providers & Services industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Numinus Wellness and its competitors. Numinus Wellness's current YoY EBITDA Growth is 90.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Numinus Wellness stock overvalued right now?
Numinus Wellness (NUMIF) has a current YoY EBITDA Growth of 90.00%. The current YoY EBITDA Growth is 90.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Numinus Wellness (NUMIF), the current YoY EBITDA Growth is 90.00% as of May. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Numinus Wellness Business Description

Address 801 - 33 Water Street, Vancouver, BC, CAN, V6B 1R4
Numinus Wellness Inc develops proprietary, psychedelic-centered, therapeutic products and services through its laboratory and research & development processes. The company's clinic network consists of Numinus Health, Mindspace Services, and the Neurology Center of Toronto. Its services include Ketamine-assisted psychotherapy for depression, neurological care, psychotherapy, and counseling by registered psychologists among others. The company's operating segments are; Clinical research operations, Canadian clinic network, US clinic network and Corporate. The majority of the revenue for the company is generated from US clinic network segment. Geographically, the company has its presence in United States and Canada.